Current Clinical Trials
Brainshuttle AD (Roche) — RO7126209 in Prodromal or Mild to Moderate Alzheimer’s (Phase 1/2)
Status: Active, not recruiting
Design: A Phase Ib/IIa randomized, double-blind, placebo-controlled, multiple ascending dose, parallel-group study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of RO7126209 following intravenous infusion in participants with prodromal or mild to moderate Alzheimer’s disease.
Who may qualify: Adults aged 50–85 years with prodromal or mild to moderate Alzheimer’s disease, MMSE 18–28, CDR 0.5–2, amyloid positive on PET. Must have a study partner, meet health requirements, and be able to undergo MRI, lumbar puncture, PET, and other study procedures.
Protocol: BP42155
ClinicalTrials.gov ID: NCT04639050
Sponsor: Hoffmann-La Roche
Principal Investigator: Dr. Monica Crane
Location: Tennessee Memory Disorders Foundation & Clinic
ALZ-NET — Alzheimer’s Network for Treatment & Diagnostics
Sponsored by: Alzheimer’s Association
Managed by: American College of Radiology
Principal Investigator: Dr. Monica Crane
POLARIS-AD — AR1001 in Early Alzheimer’s (Phase 3)
Status: Active, not recruiting
Protocol: AR1001-ADP3-US01
ClinicalTrials.gov ID: NCT05531526
Sponsor: AriBio Co., Ltd.
Principal Investigator: Dr. Monica Crane
Design: A Phase 3 double-blind, randomized, placebo-controlled, multi-center, parallel-group comparison pivotal study to evaluate the efficacy and safety of AR1001 for the treatment of participants with early Alzheimer’s disease.
Who may qualify: Male or female participants aged 55 to 90 years with mild cognitive impairment or mild dementia consistent with Alzheimer’s disease, meeting study criteria including positive amyloid biomarkers, and having an eligible study partner.
Location: Tennessee Memory Disorders Foundation & Clinic
EVOKE-Plus — Oral Semaglutide in Early Alzheimer’s (Phase 3)
Status: Active, not recruiting
Design: Primary Purpose: Treatment. Allocation: Randomized. Interventional Model: Parallel Assignment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Who may qualify: Male or female, aged 55–85 years. MCI or mild dementia of the Alzheimer’s type according to the NIA-AA 2018 criteria. CDR global score of 0.5 (with ≥0.5 in ≥1 instrumental ADL category) or 1.0. RBANS delayed memory index ≤85. MMSE ≥22. Amyloid positivity established with amyloid PET or CSF. Participants must have a study partner. Women cannot take part if pregnant, breastfeeding or plan to become pregnant during the study period.
Sponsor: Novo Nordisk A/S
ClinicalTrials.gov ID: NCT04777409
Principal Investigator: Dr. Monica Crane
Location: Tennessee Memory Disorders Foundation & Clinic
TRAILRUNNER-ALZ 3 (LAKI) — Remternetug vs Placebo in Early Alzheimer’s (Phase 3)
Status: Recruiting
Design: Randomized, double-blind, placebo-controlled, parallel-group study evaluating whether remternetug delays the onset or worsening of memory, thinking, or daily functioning problems in early Alzheimer’s disease.
Who may qualify: Adults with early Alzheimer’s disease who meet study criteria, including amyloid confirmation and other health requirements. Participation includes screening, treatment, observation, and possible open-label extension.
Protocol: J1G-MC-LAKI
ClinicalTrials.gov ID: NCT06653153
Sponsor: Eli Lilly and Company
Principal Investigator: Dr. Monica Crane
Location: Tennessee Memory Disorders Foundation & Clinic